NATIONAL COALITION FOR CANCER SURVIVORSHIP
CANCER POLICY ROUNDTABLE, APRIL 2014
FACULTY BIOGRAPHIES

Affordable Care Act: Enrollment Update and Adequacy of Exchange Plans for Cancer Patients

TANISHA CARINO, PHD
As Executive Vice President of Avalere Health, Tanisha Carino oversees Avalere's strategic advisory and research services for the nation's leading life sciences companies. For close to a decade, Tanisha has worked with senior leadership in FORTUNE 500 companies to establish organizational goals and align their internal functions to capture opportunities and mitigate challenges related to evolving regulatory, evidence, and commercial trends. Tanisha is a recognized thought leader in health technology assessments and comparative effectiveness research and the role of quality and performance measurement in U.S. healthcare and established Avalere's Center on Evidence Based Medicine in 2006.

Prior to joining Avalere, Tanisha was a policy analyst in the Coverage and Analysis Group at the Centers for Medicare & Medicaid Services. Tanisha has a PhD in Health Policy from Johns Hopkins University and is a Fulbright scholar. She serves as an associate faculty member in Johns Hopkins Bloomberg School of Public Health, is a member of the National Advisory Council for the Robert Wood Johnson Foundation's Health Care Financing and Organization program, and is a board member of Bread for the City in Washington, DC.

EMILY MUELLER, MD, MSC
Emily Mueller is currently at the University of Michigan completing a Pediatric Hematology-Oncology Fellowship at C.S. Mott Children's Hospital and a Pediatric Health Services Research Fellowship through the Child Health Evaluation and Research Unit. Dr. Mueller received her Masters of Health and Health Care Research at the University of Michigan. She attended Rush University School of Medicine in Chicago, Illinois and completed her residency training in pediatrics at Hope Children's Hospital in Oak Lawn, Illinois. One of her primary research interest is in evaluating outcomes data for childhood cancer survivors as well as investigating the influence of health disparities in regards to utilization of resources and impact on quality of life.

SOPHIE STERN, MPH
Sophie Stern is the Deputy Director of the Best Practices Institute at Enroll America, a nonprofit, nonpartisan organization whose mission is to ensure that all Americans are enrolled in and retain health coverage. The Best Practices Institute identifies, develops, and disseminates information on enrollment policies that will result in the most Americans enrolling in health coverage.

Prior to joining Enroll America, Ms. Stern was a Senior Consultant, Health Policy Specialist with the Deloitte Center for Health Solutions, where she served as a resource for Deloitte practitioners and executive-level clients on regulatory and legislative policies related to health reform and other major health policies. Before that, she served as a Policy Analyst for the Bazelon Center for Mental Health Law, where she provided technical assistance to states interested in reforming their public mental health

systems and advocated for mental health policy issues on Capitol Hill. Ms. Stern holds an MPH in Health Policy and B.S. in Public Health from the George Washington University.

JOANN VOLK, MA
JoAnn Volk is a Research Professor and Project Director at the Georgetown University Health Policy Institute. She directs research on health insurance reform issues as they affect consumers, including implementation of exchanges and the new insurance market rules under the Affordable Care Act.

Prior to joining the Institute, Ms. Volk managed health care policy and advocacy for the AFL-CIO. From 2001 to 2010, she represented the Federation on a broad range of health care issues, including employer-sponsored coverage, Medicaid, CHIP, Medicare, health care quality, and health care workforce issues. Key areas of work included the Affordable Care Act, the Medicare Modernization Act and the Health Coverage Tax Credit for laid off workers. Before coming to the AFL-CIO, Ms. Volk was a senior analyst with Abt Associates, doing research on state-based efforts to cover the uninsured and state high-risk pools. Her career began in New York State politics, working primarily as an aide to the Speaker of the New York State Assembly.

Targeted Therapies: Encouraging Regulatory and Treatment Strategies that will Ensure Patient Access

JOHN COX, OD, FACP, FASCO
John Cox is board certified and specializes in internal medicine, medical oncology, and hematology. He serves on the medical staff of Methodist Hospitals of Dallas, where he is past president of the medical staff. Dr. Cox also serves as editor-in-chief of the *Journal of Oncology Practice*, and is active in both the Texas Society of Clinical Oncology and the American Society of Clinical Oncology.

ANDREW FISH, JD
Andrew Fish is Executive Director of AdvaMedDx, the U.S. trade association representing leading manufacturers of medical diagnostic tests. AdvaMedDx operates as a division of AdvaMed, the medical device manufacturers association, where Mr. Fish holds the title of Senior Executive Vice President. Mr. Fish has extensive government relations, legal, regulatory, and policy background in food, drug, health, and agriculture issues. Prior to joining AdvaMedDx in 2010, Mr. Fish was Senior Vice President of Legal and Government Affairs, General Counsel, and Secretary for the Consumer Healthcare Products Association (CHPA), representing manufacturers of non-prescription medicines.

Mr. Fish also worked for the American Cancer Society as Senior Director of Federal Government Relations. Earlier in his career, he served in the Senate-confirmed post of Assistant Secretary of Agriculture for Congressional and Intergovernmental Affairs, after twice working for the U.S. Senate Agriculture Committee, first as a professional staff member and later as deputy chief counsel. Mr. Fish's work in private practice focused on biotech regulation, as well as on a wide range of food, drug and agriculture issues. Mr. Fish is a graduate of Yale University and Stanford Law School.

ALBERTO GUTIERREZ, PHD
Alberto Gutierrez is the director of the Office of In Vitro Diagnostic Device Evaluation and Safety, in the Center for Devices and Radiological Health at the Food and Drug Administration. Dr. Gutierrez has had a longstanding career with the FDA, joining in 1992 as a reviewer in the FDA's Center for Biologics Evaluation and Research working on vaccine adjuvants and method development for determination of

the purity and structure of vaccine components. In 2000, he joined the FDA Center for Devices and Radiological Health as a scientific reviewer, becoming a team leader for Toxicology in 2003, director of the Division of Chemistry and Toxicology Devices in 2005, deputy director of the Office of In Vitro Diagnostic Device Evaluation and Safety in 2007, and office director in 2009. He holds a bachelor's degree from Haverford College and master and doctorate degrees in chemistry from Princeton University.

GAIL H. VANCE, MD
Gail Vance received her M.D. in 1980 from Michigan State University, East Lansing, Michigan. She has been with the Indiana University Department of Medical and Molecular Genetics since September, 1989. From 1989 to 1992, she served as a Visiting Assistant Professor. In 1992, she was appointed assistant professor in the Department of Medical and Molecular Genetics and promoted to associate professor in 1998. Dr. Vance assumed the duties of assistant director of the Cytogenetic Laboratories in 1994 and director of the laboratories in 1998. Dr. Vance was appointed Interim Chairperson of the Department of Medical and Molecular Genetics in March, 1999. Dr. Vance is certified in Pediatrics (American Board of Pediatrics), Clinical Pathology (American Board of Pathology), and in Clinical Genetics and Clinical Cytogenetics (American Board of Medical Genetics). She holds the rank of Professor in the Department of Medical & Molecular Genetics, and the Department of Pathology & Laboratory Medicine.

With Cindy Hunter, M.S., Dr. Vance directs the Indiana Familial Cancer Program, which provides genetic counseling, risk assessment and genetic testing to individuals with an elevated risk for developing cancer. Currently, the IFCC offers counseling for patients with high risk for breast and ovarian cancer, familial adenomatous polyposis, and hereditary non-polyposis colon cancer, Li Fraumeni syndrome and other familial cancer syndromes. She also directs the state's only Familial Pancreatic Cancer Registry, which collects information on patients with family histories of pancreatic cancer. Dr. Vance also serves as a clinical geneticist, seeing families in genetics clinics held in Indianapolis, Carmel, and Evansville.

Bundles or Episodes of Care: Are These Payment Models Workable for Cancer Care?

EMILY OSHIMA LEE, MA
Emily Oshima Lee is a Policy Analyst with the Health Policy team at American Progress. Her work focuses primarily on analyzing and developing policies related to creating a higher-value health care system. Emily's work has appeared in The New England Journal of Medicine and Annals of Internal Medicine. Prior to joining American Progress, Emily served as a national program coordinator with the International Group of the YMCA of the USA. Her experience also includes work with the science, medical, and public health group of the American Medical Association in Chicago, Illinois, where she worked on Affordable Care Act policies with an emphasis on health outcomes for vulnerable populations. Emily's prior experience also includes work with low-income, HIV-positive families in a managed-care setting. Originally from Hawaii, Emily holds a master's degree from the University of Chicago and a B.A. from Northwestern University.

JOHN O'SHEA, MD, MPA, FACS
John O'Shea is currently a Visiting Scholar in the Engelberg Center for Health Care Reform, Department of Economic Studies, at the Brookings Institution in Washington, DC, where he works on the development of alternative payment and delivery models, among other issues. Prior to joining

Brookings, Dr. O'Shea was Senior Health Policy Advisor to the Energy and Commerce Committee, US House of Representatives, where he worked on a number of health care issues, including Medicare physician payment reform. He has been a practicing general surgeon for more than 25 years. He completed his surgical training in New York City and prior to working for the Energy and Commerce Committee, he was an assistant professor of surgery at the Albert Einstein College of Medicine and Montefiore Medical Center in the Bronx, NY. He has a Masters in Public Administration from the Harvard Kennedy School of Government as well as a Masters in the History and Sociology of Science from the University of Pennsylvania.

STEVE SPAULDING

Steve Spaulding is Senior Vice President, Enterprise Networks, for Arkansas BlueCross BlueShield. He has executive responsibility for the payment reform initiative, the establishment of collaborative health ventures, oversight of the patient-centered medical homes, enterprise network contracting, hospital reimbursement, and enterprise pharmacy programs. Spaulding joined Arkansas Blue Cross and Blue Shield in 1983 as a marketing representative in the Hot Springs region and was named an account executive in 1991 for USAble Administrators. He was named regional marketing manager for eastern Arkansas in 1993. He served as regional executive of the South Central region headquartered in Hot Springs from 1994 until 2002, when he was promoted to vice president of Internal Operations. In 2008, he was promoted to vice president of Enterprise Networks. A native of Breckenridge, Mich., Spaulding received his bachelor's degree from Alma College in Michigan. He is a chartered life underwriter and a certified health consultant. He received Professional status in the Association of Healthcare Management in 2005.

JOHN SPRANDIO, M.D.

John Sprandio is Chief of Medical Oncology and Hematology at Delaware County Memorial Hospital, Director of the Delaware County Regional Cancer Center, and a member of the Fox Chase Network. Board certified in Internal Medicine, Medical Oncology and Hematology, Dr. Sprandio received his Medical Degree from Temple University School of Medicine, completed internship and residency at Pennsylvania Hospital and Fellowship in Medical Oncology and Hematology at Thomas Jefferson University Hospital. He is the lead physician of a single specialty, Hematology and Oncology practice, Consultants in Medical Oncology and Hematology, P.C in Delaware County, Pennsylvania. He is a Fellow of the American College of Physicians, and member of the American Society of Clinical Oncology and the American Society of Hematology. His efforts in, "Making a Business case for quality", led to his oncology practice becoming the first specialty practice to be recognized by the National Committee for Quality Assurance as a level III Patient Centered Medical Home. He is the founder and managing partner of Oncology Management Services, Inc., a consulting firm providing transformation related services including specialty practice assessments, staff and physician education, strategies for re-engineering care, symptom management guidelines, and physician-centric IT solutions focused on merging processes of care, data presentation, decision support, care coordination and communication. He has spoken widely regarding the Oncology Patient Centered Medical Home model and is dedicated to continuously improving the quality and value of cancer care.

PETER P. YU, MD, FASCO

Peter P. Yu, MD, FASCO, is a medical oncologist and hematologist at Palo Alto Medical Foundation, where he is also Director of Cancer Research. Dr. Yu has been at Palo Alto Medical Foundation since 1989. He was elected President of the American Society of Clinical Oncology (ASCO) for a one-year term beginning in June 2014.

Since joining ASCO in 1986, Dr. Yu has served on the Quality of Care Committee (2011-2013), Strategic Planning Committee (2010-2013), Health Information Technology Workgroup (Chair, 2009-present), Integrated Media and Technology Committee (2010-2012), Board of Directors (2009-2012), Cancer Research Committee (2010-2011; 2004-2007), Clinical Practice Committee (2004-2008; Chair, 2006-2007), and Best of ASCO Planning Committee (2003-2007; Chair, 2004-2005), among others. He was also ASCO State Affiliate Society President of the Association of Northern California Oncologists (ANCO; 2004-2006) and is currently an ASCOconnection.org blogger. He was Co-Chair of the ASCO-NCI Clinical Oncology Requirements for the EHR Committee (2008).

In addition to his ASCO involvement, Dr. Yu is a member of the Cancer and Leukemia Group B as well as the Gynecologic Oncology Group. He is a member of the Commission for the Certification of Health Information Technology Workgroups on Research and Oncology (Co-Chair). He received his medical degree from Brown University, and performed his internship and residency in Internal Medicine at St. Luke's-Roosevelt Hospital and a fellowship in Neoplastic Diseases at Mount Sinai Hospital. Dr. Yu was also a Research Fellow and Associate at Memorial Sloan-Kettering Cancer Center.

Balancing Risk and Benefit in Cancer Drugs

Getting New Medicines to Patients Faster: Innovative Approaches

PETER C. ADAMSON, MD

Peter Adamson is Chair of the Children's Oncology Group (COG), a National Cancer Institute (NCI) supported international consortium of more than 220 childhood centers that conducts clinical-translational research, including large-scale clinical trials, in children with cancer. He is Professor of Pediatrics and Pharmacology at the University of Pennsylvania School of Medicine and Chief of the Division of Clinical Pharmacology and Therapeutics at The Children's Hospital of Philadelphia (CHOP). Dr. Adamson is Board Certified in Pediatric Hematology/Oncology and in Clinical Pharmacology. He is an internationally recognized leader in pediatric cancer drug development, having served until 2008 as Chair of the COG's Developmental Therapeutics Program. Prior to becoming Chair of the COG in 2011, Dr. Adamson served as Director for Clinical and Translational Research at The Children's Hospital of Philadelphia. Other key roles that he has served include co-Director of the University of Pennsylvania's - CHOP Clinical Translational Science Award (CTSA), Program Director of the General Clinical Research Center (GCRC) and Principal Investigator of CHOP's NICHD-funded Pediatric Pharmacology Research Unit (PPRU). His laboratory focuses on the clinical pharmacology of new drugs for childhood cancer.

BOB ERWIN, MS

Bob Erwin has been the President of iBio, Inc. (formerly iBioPharma, Inc.), a subsidiary of Integrated Biopharma Inc. since August 2008. Mr. Erwin co-founded Large Scale Biology Corp. in 1987 and served as its President from 1988 to 1992 and Chief Executive Officer from 1992 to April 2003. He is a Co-Founder of Marti Nelson Cancer Foundation and serves as its President. Prior to Large Scale Biology Corp., Mr. Erwin Co-founded Sungene Technologies Corporation and served as its Vice President of Research and Product Development from 1981 to 1986. He served as the Managing Director of Bio-Strategic Directors LLC. Mr. Erwin's non-profit work focuses on applying scientific advances to clinical medicine, especially in the field of oncology. He serves as the Chairman of Novici Biotech, a private biotechnology company. Mr. Erwin served as the Chairman of Large Scale Biology Corp., from 1992 to 2006. He serves as a Director of Resolve Therapeutics. He serves as a Director of Marti Nelson Cancer Foundation. He served

as a Director of Large Scale Biology Corp. since 1987. He is a Member of the Research Committee of the American Society of Clinical Oncology. Mr. Erwin holds a BS in Zoology and an MS in Genetics from Louisiana State University.

ANGELA DEMICHELE, MD, MSCE

Angela DeMichele is an Associate Professor of Medicine and Epidemiology at the University of Pennsylvania and Senior Scholar in the Center for Clinical Epidemiology and Biostatistics. She co-leads the Breast Cancer Research Program of the Abramson Cancer Center and directs the Doris Duke Clinical Research Fellowship Program at the University of Pennsylvania. Dr. DeMichele earned a B.S. in Biochemistry from Brown University, an M.D. from Washington University School of Medicine (as a Four Schools Physician/Scientist Scholar) and a Masters Degree in Clinical Epidemiology from the University of Pennsylvania. She received her clinical training in Internal Medicine and Hematology/Oncology at the University of Pennsylvania, and joined the faculty in 2000 as a breast cancer oncologist and molecular epidemiologist whose research focuses on identifying markers of outcome, response to therapy and development of targeted therapeutics.

Dr. DiMichele is currently the principal investigator of numerous clinical trials and epidemiologic studies, including Chair of Trial Operations for the I-SPY2 Trial, a multicenter clinical trial in which targeted therapeutics are tested in the context of molecular and MRI imaging response profiles in patients receiving neoadjuvant therapy for locally-advanced breast cancer, and her work has been funded through the NCI and other charitable foundations. In addition, she directs Penn's Breast Cancer Survivorship Program, a multidisciplinary clinical research program at the Abramson Cancer Center, where she and her colleagues are performing studies of bone loss, ovarian dysfunction, hot flashes, lymphedema, depression/distress and physical activity in breast cancer survivors. She is a past recipient of a Young Investigator Award from the American Society of Clinical Oncology, a Clinical Research Training Grant from the American Cancer Society and a Patient-Oriented Career Development Award from the NIH. Dr. DeMichele has served on the American Board of Internal Medicine Oncology Subspecialty Board, the Editorial Board of the Journal of Clinical Oncology and is currently Chair of the Medical Advisory Board of the Expedition Inspiration Fund for Breast Cancer Research.

GREGORY REAMAN, MD

Greg Reaman is the associate director for oncology sciences, Office of Hematology and Oncology Products, Center for Drug Evaluation and Research at the FDA, and executive director emeritus of the Center for Cancer and Blood Disorders and senior attending physician at Children's National Medical Center, Washington, D.C. Throughout his career, Reaman has held numerous leadership positions. He was the Inaugural Chair of the Children's Oncology Group and previously served as the Associate Chair for New Agent Studies and Vice Chair for Scientific Affairs of the Children's Cancer Group. He served on the national Board of Directors of the American Cancer Society and chaired its Task Force on Cancer in Children and on the Board of Directors of the American Society of Clinical Oncology and is currently a member of the Nominating Committee. He was a member of the FDA's Oncologic Drugs Advisory Committee and chaired its Pediatric Subcommittee. He directed the Department of Hematology/Oncology, at Children's National Medical Center; and he is a professor of pediatrics at the George Washington University School of Medicine and Health Sciences. Dr. Reaman was recently honored with the Leukemia and Lymphoma Society's Return of the Child Award, which is given to those who have played a major role in improving the outcome and quality of life of children with leukemia and other cancers and their families.

WENDY K.D. SELIG, MS

Wendy K.D. Selig is President and CEO of the Melanoma Research Alliance (MRA), a public charity focused on finding and funding the most promising translational melanoma research worldwide that will accelerate progress toward a cure. Ms. Selig drives and manages MRA's strategic priorities, research portfolio, engagement with more than 90 corporate and non-profit Allies, and day-to-day operations. MRA, founded by Debra and Leon Black under the auspices of the Milken Institute, is the largest private funder of melanoma research, awarding $8-10 million in new grants each year. Ms. Selig has held leadership roles in numerous coalitions, including United for Medical Research (UMR) and Once Voice Against Cancer (OVAC). She has served on the National Cancer Institute (NCI) Director's Consumer Liaison Group (DCLG). She is also a member of the Patient Leadership Council of the Clinical Trials Transformation Initiative (CTTI) and the Government Affairs Committee of the Prostate Cancer Foundation (PCF).

Prior to joining the MRA, Ms. Selig spent nearly a decade in leadership positions at the American Cancer Society (the Society) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Most recently, she served as ACS CAN's Vice President of External Affairs & Strategic Alliances where she built strategic partnerships with corporations, foundations, trade associations, and federal agencies. Ms. Selig's work with the Society and ACS CAN began in 2000, when she served first as Managing Director, Federal Government Relations and later Vice President for Legislative Affairs. From 1989-2000, Ms. Selig served on Capitol Hill as a senior staff member for U.S. Representative Porter J. Goss (R-FL), the House Rules Committee and the House Permanent Select Committee on Intelligence (HPSCI). A native of Princeton, NJ, Ms. Selig is a Magna Cum Laude graduate of Princeton University and holds a Masters in Science (With Distinction) from Northwestern University's Medill School of Journalism.

Moderators

SHELLEY FULD NASSO, MPP

As Chief Executive Officer of the National Coalition for Cancer Survivorship, Shelley Fuld Nasso has responsibility for managing all facets of NCCS, including planning and executing the public policy activities of the organization at a time of rapid and fundamental health care system change. Prior to joining NCCS, Shelley served in leadership roles at Susan G. Komen, where she leveraged the strength of Komen's grassroots network to strengthen the organization's reputation and visibility in Washington, D.C., and in state capitals. Shelley has also served as Director of Community Philanthropy at The Dallas Foundation and held management positions at communications and technology enterprises. She is a graduate of Rice University and holds a Master of Public Policy from the Harvard Kennedy School. Her commitment to the work of NCCS is strongly tied to the experiences in the cancer care system of her dear friend, Dr. Brent Whitworth, a beloved physician diagnosed with stage IV cancer days before his 42nd birthday. Through Brent's battle, Shelley witnessed the strengths and flaws of the cancer care system and embraces the notion that policy change can directly benefit patients and caregivers going through this journey.